{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:30:22Z","timestamp":1792114222480,"version":"4.4.0"},"reference-count":17,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic hepatitis delta (CHD) affects approximately 10\u201320\u00a0million people worldwide and represents the most severe form of chronic viral hepatitis, as it is characterized by high rates of progression to cirrhosis and its complications (end\u2010stage liver disease, hepatocellular carcinoma). In the last 30\u2009years, the only treatment option for CHD has been represented by the off\u2010label administration of Interferon (or Pegylated Interferon)\u2010alpha: antiviral treatment, however, resulted in suboptimal (20\u201330%) virological response and was burdened by several side effects, de facto contraindicating Interferon (IFN) administration in patients with more advanced liver disease. Recently, Bulevirtide (BLV), a first\u2010in\u2010class HBV\u2010HDV entry inhibitor blocking Na<jats:sup>+<\/jats:sup>\u2010taurocholate co\u2010transporting polypeptide (NTCP), has provided very promising efficacy data in Phase II and Phase III (interim analysis) trials as well as in preliminary real\u2010life reports. In July 2020, BLV has granted conditional approval by EMA for treatment of compensated CHD, at the dose of 2\u00a0mg\/day by self\u2010administered subcutaneous injections. In Phase II and Phase III trials, BLV was evaluated at different doses (2 vs. 10\u2009mg\/day) for 24 or 48\u2009weeks, either in monotherapy or in combination with PegIFN. Administration of BLV monotherapy for 24 or 48\u2009weeks resulted in 50%\u201383% virological response (HDV RNA\u2009\u2265\u20092 Log decline) rates and 45%\u201378% ALT normalization. Combination therapy with PegIFN provided synergistic effects. These results were replicated in real\u2010life studies and confirmed also in patients with advanced cirrhosis and clinically significant portal hypertension. BLV treatment was optimally tolerated, resulting only in an asymptomatic increase of bile acids.<\/jats:p>","DOI":"10.1111\/liv.15389","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T07:48:41Z","timestamp":1660031321000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Bulevirtide for patients with compensated chronic hepatitis delta: A review"],"prefix":"10.1111","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-4669","authenticated-orcid":false,"given":"Elisabetta","family":"Degasperi","sequence":"first","affiliation":[{"name":"Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Division of Gastroenterology and Hepatology  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Anolli","sequence":"additional","affiliation":[{"name":"Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Division of Gastroenterology and Hepatology  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-7476","authenticated-orcid":false,"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[{"name":"Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Division of Gastroenterology and Hepatology  Milan Italy"},{"name":"CRC \u201cA. M. and A. Migliavacca\u201d Center for Liver Disease, Department of Pathophysiology and Transplantation University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.008"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30663-7"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323888"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2018.04.004"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.016"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30224-1"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30651-6"},{"key":"e_1_2_9_10_1","first-page":"S291","article-title":"Safety and efficacy of bulevirtide monotherapy and in combination with peginterferon alfa\u20102a in patients with chronic hepatitis delta: 24\u2010week interim data of MYR204 phase 2b study","volume":"75","author":"Asselah A","year":"2021","journal-title":"J Hepatol"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(22)00433-0"},{"key":"e_1_2_9_12_1","first-page":"S148A","article-title":"Strong intrahepatic decline of hepatitis D virus RNA and antigen after 48\u2009weeks of treatment with bulevirtide in chronic HBV\/HDV co\u2010infected patients: interim results from a multicenter, open\u2010label, randomized phase 3 clinical trial (MYR301)","volume":"74","author":"Allweiss L","year":"2021","journal-title":"Hepatology"},{"key":"e_1_2_9_13_1","first-page":"S16A","article-title":"Safety and efficacy of 2 mg bulevirtide in patients with chronic HBV\/HDV co\u2010infection. First real\u2010world results (French early access program)","volume":"74","author":"De Ledinghen V","year":"2021","journal-title":"Hepatology"},{"key":"e_1_2_9_14_1","article-title":"Early clinical and virological changes in HDV patients with advanced cirrhosis treated with bulevirtide monotherapy in a real\u2010life setting","volume":"74","author":"Loglio A","year":"2021","journal-title":"Hepatology"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.10.012"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14950"},{"issue":"745","key":"e_1_2_9_17_1","first-page":"PO\u20101419","article-title":"First real\u2010life experiences with 2 mg bulevirtide for the treatment of hepatitis delta\u2010data from a tertiary reference Centre in Germany","volume":"75","author":"Z\u00f6llner C","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"e_1_2_9_18_1","first-page":"420A","article-title":"Efficacy of long\u2010term treatment of chronic hepatitis D patients with bulevirtide \u2013 results of a \u201creal world\u201d study","volume":"74","author":"Binter T","year":"2021","journal-title":"J Hepatol"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.15389","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.15389","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.15389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T07:31:54Z","timestamp":1693639914000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.15389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":17,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/liv.15389"],"URL":"https:\/\/doi.org\/10.1111\/liv.15389","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"2022-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}